atrasentan has been researched along with Anasarca in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awni, WM; J Brennan, J; Klein, CE; L Andress, D; Lin, CW; Mostafa, NM | 1 |
| Andress, D; Brennan, JJ; Busch, R; Coll, B; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Houser, M; Kohan, D; Makino, H; Parving, HH; Pergola, P; Perkovic, V; Pritchett, Y; Remuzzi, G; Tobe, SW; Toto, R; Webb, DJ | 1 |
| Chapman, M; Kohan, DE; Rees, S; Stuart, D; Woodward, S | 1 |
| Holmes, DR; Kent, B; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E | 1 |
| Andress, DL; Brennan, J; Coll, B; Kohan, DE; Molitch, M; Pritchett, Y | 1 |
| Albertini, M; Clement, MG; Hussain, SN | 1 |
| Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR | 1 |
| D'Orléans-Juste, P; Piovezan, AP; Rae, GA; Souza, GE | 1 |
4 trial(s) available for atrasentan and Anasarca
| Article | Year |
|---|---|
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Electric Impedance; Endothelin Receptor Antagonists; Female; Humans; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Renin-Angiotensin System; Weight Gain | 2017 |
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.
Topics: Adult; Antihypertensive Agents; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Edema; Endothelin A Receptor Antagonists; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension; Kidney; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pyrrolidines; Receptor, Endothelin A; Risk Factors; Treatment Outcome | 2008 |
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Topics: Aged; Albuminuria; Atrasentan; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Edema; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Hispanic or Latino; Humans; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid | 2006 |
4 other study(ies) available for atrasentan and Anasarca
| Article | Year |
|---|---|
Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.
Topics: Aged; Albuminuria; Atrasentan; Body Weight; Clinical Trials, Phase II as Topic; Creatinine; Diabetic Nephropathies; Double-Blind Method; Edema; Female; Humans; Kidney Function Tests; Male; Middle Aged; Randomized Controlled Trials as Topic | 2018 |
Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention.
Topics: Animals; Atrasentan; Body Fluids; Edema; Endothelin A Receptor Antagonists; Kidney Tubules, Collecting; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocardium; Nephrons; Organ Specificity; Phenylpropionates; Pyridazines; Pyrrolidines; Receptor, Endothelin A; Sodium Chloride, Dietary; Species Specificity | 2013 |
Role of endothelin ETA receptors in sepsis-induced mortality, vascular leakage, and tissue injury in rats.
Topics: Animals; Atrasentan; Disease Models, Animal; Edema; Endothelin A Receptor Antagonists; Male; Multiple Organ Failure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sepsis | 2003 |
Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation.
Topics: Animals; Atrasentan; Capsaicin; Edema; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hyperalgesia; Male; Mice; Nociceptors; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Viper Venoms | 2000 |